KR20080093500A - Roe deer urine extract - Google Patents
Roe deer urine extract Download PDFInfo
- Publication number
- KR20080093500A KR20080093500A KR1020070037245A KR20070037245A KR20080093500A KR 20080093500 A KR20080093500 A KR 20080093500A KR 1020070037245 A KR1020070037245 A KR 1020070037245A KR 20070037245 A KR20070037245 A KR 20070037245A KR 20080093500 A KR20080093500 A KR 20080093500A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- roe deer
- deer urine
- cosmetic composition
- urine extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000284 extract Substances 0.000 title claims abstract description 82
- 241000282988 Capreolus Species 0.000 title claims abstract description 73
- 210000002700 urine Anatomy 0.000 title claims abstract description 67
- 239000000203 mixture Substances 0.000 claims abstract description 61
- 239000002537 cosmetic Substances 0.000 claims abstract description 49
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 28
- 108010035532 Collagen Proteins 0.000 claims abstract description 27
- 102000008186 Collagen Human genes 0.000 claims abstract description 27
- 229920001436 collagen Polymers 0.000 claims abstract description 27
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 27
- 230000009759 skin aging Effects 0.000 claims abstract description 24
- 210000004927 skin cell Anatomy 0.000 claims abstract description 17
- 102000006495 integrins Human genes 0.000 claims abstract description 15
- 108010044426 integrins Proteins 0.000 claims abstract description 15
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 13
- 230000035755 proliferation Effects 0.000 claims abstract description 12
- 238000009472 formulation Methods 0.000 claims description 23
- 102000029816 Collagenase Human genes 0.000 claims description 16
- 108060005980 Collagenase Proteins 0.000 claims description 16
- 229960002424 collagenase Drugs 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000006071 cream Substances 0.000 claims description 13
- 239000006210 lotion Substances 0.000 claims description 13
- 230000001737 promoting effect Effects 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 10
- -1 pack Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 230000002708 enhancing effect Effects 0.000 claims description 7
- 239000000686 essence Substances 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 40
- 230000037303 wrinkles Effects 0.000 abstract description 22
- 210000002950 fibroblast Anatomy 0.000 abstract description 13
- 230000037394 skin elasticity Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 description 19
- 230000006872 improvement Effects 0.000 description 16
- 239000004615 ingredient Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 230000032683 aging Effects 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 7
- 238000002845 discoloration Methods 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 238000000605 extraction Methods 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 230000002335 preservative effect Effects 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 230000007760 free radical scavenging Effects 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 4
- 229940113124 polysorbate 60 Drugs 0.000 description 4
- 241001092376 Astilbe Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 2
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 2
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 2
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 102000012355 Integrin beta1 Human genes 0.000 description 2
- 108010022222 Integrin beta1 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000229537 Moxostoma Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 108010050808 Procollagen Proteins 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001133946 Actinokentia Species 0.000 description 1
- 241000246866 Astilbe koreana Species 0.000 description 1
- 241000245731 Astilbe simplicifolia Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000008217 Pregnancy Proteins Human genes 0.000 description 1
- 108010035746 Pregnancy Proteins Proteins 0.000 description 1
- 208000034874 Product colour issue Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940079894 benzophenone-9 Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000012830 plain croissants Nutrition 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 피부 노화 방지용 화장료 조성물에 관한 것으로, 보다 상세하게는 노루오줌 추출물이 함유되어 피부 노화를 방지하는 화장료 조성물에 관한 것이다. 본 발명에 따라면, 노루오줌 추출물이 피부 세포의 증식을 촉진시키고 섬유아세포의 콜라겐 합성 촉진 및 분해를 억제하며 인테그린의 발현을 증진시키고 뛰어난 항산화 효과를 발휘하여 피부 주름을 개선시키고 피부의 탄력을 증진시켜 피부 노화를 방지한다. The present invention relates to a cosmetic composition for preventing skin aging, and more particularly, to a cosmetic composition containing a roe deer urine extract to prevent skin aging. According to the present invention, the roe deer urine extract promotes the proliferation of skin cells, inhibits the synthesis and synthesis of fibroblast collagen synthesis, enhances the expression of integrin and exerts an excellent antioxidant effect to improve skin wrinkles and enhance skin elasticity. Prevents skin aging.
Description
본 발명은 노루오줌 추출물을 함유하는 피부 노화 방지용 화장료 조성물에 관한 것으로, 더욱 상세하게는 노루오줌 추출물이 함유되어 피부 세포의 증식을 촉진시키고, 섬유아세포의 콜라겐 합성 촉진 및 분해를 억제하며, 인테그린의 발현을 증진시키고, 뛰어난 항산화 효과를 가져 피부 주름 개선과 피부 탄력 개선을 통해 피부 노화를 효과적으로 방지하는 화장료 조성물에 관한 것이다. The present invention relates to a cosmetic composition for preventing skin aging containing roe deer urinary tract extract, and more particularly, containing roe deer urine extract to promote the proliferation of skin cells, to inhibit the synthesis and synthesis of collagen of fibroblasts, It relates to a cosmetic composition that enhances the expression, has an excellent antioxidant effect and effectively prevents skin aging through skin wrinkle improvement and skin elasticity improvement.
피부는 인체의 가장 큰 기관으로서 전체 인체 부피의 약 16%를 차지하고 있고 외부환경과 직접 접해 있으면서 인체 안으로 침입하려는 치명적인 많은 유해인자, 예를 들면, 온도, 습도 및 자외선 등으로부터 인체를 보호하는 중요한 보호막 역할을 담당한다. 그러나, 나이가 들어감에 따라 각종 오염물질, 강한 자외선, 스트레스 및 영양결핍 등으로 인해 피부 세포들이 손상을 입게 되고, 세포 증식이 제대로 이루어지지 않게 되어 피부에 주름, 탄력 손실 및 각질화 등이 발생한다.The skin is the largest organ of the human body, occupying about 16% of the total body volume, and an important protective barrier that protects the body from many deadly harmful factors, such as temperature, humidity, and ultraviolet radiation, which are in direct contact with the external environment and are likely to enter the body. Play a role. However, as they age, skin cells are damaged due to various contaminants, strong ultraviolet rays, stress, and malnutrition, and cell proliferation is not performed properly, resulting in wrinkles, loss of elasticity, and keratinization.
피부의 노화는 크게 내인적 노화(intrinsic aging)와 외인적 노화(extrinsic aging)로 대별된다(Cosmetics & Toiletories, 111:31-37(1996)). 내인적 노화는 나이가 들어감에 따라 피부의 생리적 기능이 점차 저하되어 자연적으로 나타나는 노화 현상으로 임상학적으로 탄력이 감소하고, 피부결이 거칠어지며, 깊은 주름이 생기며 색소가 침착되는 특징이 있다(Arch Dermatol., 130:87-95(1994)). 외인적 노화는 자외선, 활성 산소종(reactive oxygen species) 및 스트레스 등의 외인적 요인에 의해 발생하는 노화 현상을 말한다. 이러한 요인들에 의해 피부의 노화가 급속히 진행되며, 그 결과 피부 표면에 거친 주름이 생성되고 탄력이 현저히 감소하게 된다.Skin aging is largely divided into intrinsic aging and extrinsic aging (Cosmetics & Toiletories, 111: 31-37 (1996)). Endogenous aging is a aging phenomenon that occurs naturally as the physiological function of the skin gradually decreases with age. Clinically, elasticity is reduced, skin texture is rough, deep wrinkles are formed, and pigments are deposited. Dermatol., 130: 87-95 (1994). Exogenous aging refers to the aging phenomenon caused by exogenous factors such as ultraviolet light, reactive oxygen species and stress. These factors lead to rapid aging of the skin, resulting in rough wrinkles on the surface of the skin and a marked decrease in elasticity.
현재, 피부의 노화 기작을 규명하기 위한 여러 연구들이 진행되어 여러 가지 피부 노화의 원인들이 밝혀졌다. 피부가 온도의 변화, 습도의 저하 또는 바람 등에 의해 건조하게 되면 외부에 대한 방어벽으로서의 피부 생리 활성이 저하되어 노화가 촉진된다. 또한, 유해 활성산소종 또는 자유 라디칼에 피부가 노출되면 체내의 산화 작용에 의해 과산화 지질이 생성되고 피부를 구성하는 여러 단백질들의 변형을 유발하게 된다. At present, various studies have been conducted to investigate the mechanism of aging of the skin and various causes of skin aging have been identified. When the skin is dried by a change in temperature, a decrease in humidity or wind, the skin physiological activity as a protective barrier against the outside is lowered to promote aging. In addition, when the skin is exposed to harmful free radicals or free radicals, lipid peroxide is produced by oxidative action in the body and causes modification of various proteins constituting the skin.
한편, 피부 진피의 대부분(피부 전체 건조 중량의 약 70-80%)을 차지하는 콜라겐과 신축성이 큰 엘라스틴 단백질은 섬유아세포에서 생성되는 주요 단백질로 피부 진피층에서 피부의 기계적 견고성, 조직의 결합력 및 탄력성 등에 관여한다(Journal of the american academy of dermatology, 21:610-613(1989)). 콜라겐은 연령이 증가할수록, 그리고 자외선에 노출이 많이 될수록 양적 감소를 보인다. 콜라겐은 형태와 구조적 특징에 따라서 분류되는데 이들 중에서, 가장 특징이 잘 알려진 것은 타입 I, II, III 그리고 IV이다. 콜라겐 타입 I과 III는 진피층의 세포간질의 구성성분을 이루고 콜라겐 타입 IV는 DEJ (Dermal Epidermal Junction)의 주요 구성물질이 된다. 콜라겐 타입 II는 피부의 표피층과 진피층 사이에 위치하여 두 층간의 물질 투과와 수송을 조절해주며 인접한 피부세포의 분화를 조절하며 피부의 견고성을 유지시켜준다. 피부의 주요 구조적 성분인 콜라겐과 엘라스틴은 자연적 또는 외부 자극에 의해 구조가 변성되거나 생합성량이 감소하게 되는데 이로 인해 피부 노화가 가속화된다. 또한 콜라게네이즈의 발현량과 활성 역시 피부 노화를 가속화시키는 주요 요인이다. On the other hand, collagen and elastic elastin proteins, which make up most of the dermis (about 70-80% of the total dry weight of the skin), are the major proteins produced by fibroblasts, and the skin's mechanical firmness, tissue binding strength and elasticity (Journal of the american academy of dermatology, 21: 610-613 (1989)). Collagen decreases with age and with increasing exposure to ultraviolet light. Collagen is classified according to form and structural features, the most well known of which are Type I, II, III and IV. Collagen types I and III constitute the constituents of the cytoplasm of the dermis, and collagen type IV is the major component of DEJ (Dermal Epidermal Junction). Collagen type II is located between the epidermal and dermal layers of the skin to regulate the permeation and transport of substances between the two layers, to control the differentiation of adjacent skin cells and to maintain the firmness of the skin. Collagen and elastin, the major structural components of the skin, are either denatured or reduced in biosynthesis by natural or external stimuli, thereby accelerating skin aging. In addition, the expression and activity of collagenase is also a major factor in accelerating skin aging.
주름 생성 및 피부 탄력의 저하는 진피층 내의 매트릭스 구조를 형성하고 있는 콜라겐 및 엘라스틴 등의 양뿐만 아니라 상기 성분의 조직화된 상태 또는 매트릭스와 피부 세포 간의 상호 작용 정도에 의해서도 영향을 받는다. Wrinkle formation and deterioration of skin elasticity are affected not only by the amount of collagen and elastin and the like that form the matrix structure in the dermal layer, but also by the organized state of the component or the degree of interaction between the matrix and skin cells.
또한, 피부 세포에 존재하는 막 단백질의 한 종류인 인테그린은 피부 세포간 접착 및 세포-단백질 간의 상호 작용에 중요한 역할을 하며, 결과적으로 피부 탄력에 영향을 미친다. 인테그린의 발현 정도가 세포 접착 정도, 즉 피부 탄력과 연관되어 있다는 것이 보고되어 있는데, UV-A 및 UV-B 조사를 통해 노화가 유도된 섬유아세포 표면의 인테그린의 발현 정도를 측정하면 조사된 세포의 인테그린 발현 정도가 조사되지 않은 세포의 인테그린 발현 정도보다 떨어진다고 보고되고 있다(Laetitia Moreau, Cosmetics &Toiletries, 118(1):75-84 2003). Integrin, a type of membrane protein present in skin cells, also plays an important role in skin cell adhesion and cell-protein interactions, which in turn affects skin elasticity. It has been reported that the level of integrin expression is related to the degree of cell adhesion, that is, the skin elasticity. When the level of integrin expression on the surface of fibroblasts induced aging by UV-A and UV-B irradiation is measured It is reported that the level of integrin expression is lower than the level of integrin expression of unirradiated cells (Laetitia Moreau, Cosmetics & Toiletries, 118 (1): 75-84 2003).
콜라겐 합성 촉진물질로 종래에는 레티노인산(retinoic acid), 표피성장인자(Epidermal growth factor: EGF), TGF(trans- forming growth factor, 발암증식 인자 Cardinale G. et al., Adv. Enzymol., 41, p. 425, 1974), 동물 태반 유래의 단백질(JP8-231370), 베툴린산(betulinic acid(JP8-208424)), 클로렐라 추출물(JP9-40523, JP10-36283, 섬유아세포 증식 촉진작용) 등이 알려져 있다. 특히 표피성장인자는 상피세포, 내피세포 및 섬유아세포 세포증식의 강력한 촉진제로 작용하며, 상피세포 결손 시 상피세포의 이동과 증식을 촉진시키기 때문에 상처치유 효과가 우수하다. 또한 레티놀은 콜라겐 합성과 분해억제에 매우 효과적으로 작용하여 피부 주름 개선 효과를 발휘하는 것으로 미국 특허 제4,603,146호 및 제4,877,805호 등에 제시되어 있다. Retinoic acid, epidermal growth factor (EGF), TGF (trans-forming growth factor), carcinogenesis factor Cardinale G. et al., Adv.Enzymol., 41, p 425, 1974), animal placental proteins (JP8-231370), betulinic acid (betulinic acid (JP8-208424)), chlorella extracts (JP9-40523, JP10-36283, fibroblast proliferation). . In particular, epidermal growth factor acts as a potent promoter of epithelial cell, endothelial cell and fibroblast cell proliferation, and promotes the movement and proliferation of epithelial cells during epithelial cell defects. Retinol is also described in US Pat. Nos. 4,603,146 and 4,877,805, which have a very effective effect on collagen synthesis and inhibition of degradation to exert skin wrinkle improvement.
그러나 레티노인산의 경우 불안정하고, 피부 적용 시 자극, 발적 등의 안정성 문제로 사용량의 제한이 있으며, 클로렐라 추출물 등은 효과가 미미하여 실질적으로 피부의 콜라겐 합성을 촉진하여 피부 기능 개선 효과를 기대할 수 없다. However, retinoic acid is unstable, and there is a limit to the amount of use due to stability problems such as irritation and redness when applying the skin. Chlorella extract and the like have little effect, so the collagen synthesis of the skin cannot be substantially expected to improve skin function.
따라서, 생체에 안전하고 기존의 콜라겐 합성능 촉진 물질보다 효과가 높은 새로운 콜라겐 합성 촉진제의 개발이 절실히 요망되고 있다. Therefore, there is an urgent need for the development of new collagen synthesis promoters which are safe for living bodies and are more effective than conventional collagen synthesis ability promoting substances.
본 발명은 상기와 같은 종래 기술의 문제점을 해결하기 위한 것으로, 피부에 자극 없이 안정하게 적용될 수 있으며, 피부 세포의 증식을 촉진시키고 섬유아세포의 콜라겐 합성 촉진 및 분해를 억제하며 인테그린의 발현을 증진시키고 뛰어난 항산화 효과를 가져 피부 주름을 개선시키고 피부의 탄력을 증진시켜 피부 노화를 방지할 수 있는 화장료 조성물을 제공하는 데에 그 목적이 있다. The present invention is to solve the problems of the prior art as described above, can be applied stably without irritation to the skin, to promote the proliferation of skin cells, to inhibit the synthesis and synthesis of collagen synthesis of fibroblasts and to enhance the expression of integrin The purpose of the present invention is to provide a cosmetic composition capable of preventing skin aging by improving skin wrinkles and improving skin elasticity by having an excellent antioxidant effect.
상기 목적을 달성하기 위하여 본 발명은 노루오줌 추출물을 유효성분으로 함유하는 피부 노화 방지용 화장료 조성물을 제공한다. 상기 노루오줌 추출물은 ⅰ) 피부 세포의 증식 촉진, ⅱ) 콜라겐의 합성 촉진, ⅲ) 콜라게네이즈의 억제, ⅳ) 인테그린 발현 증진, ⅴ) 항산화 작용, 또는 ⅵ) 이들의 조합의 작용을 나타내는 유효성분으로 함유된다. 이때, 상기 노루오줌 추출물은 조성물 총 중량에 대해서 0.001중량% ~ 20.0중량%로 함유되는 것이 바람직하다. In order to achieve the above object, the present invention provides a cosmetic composition for preventing skin aging containing a roe deer urine extract as an active ingredient. The roe deer urine extract is effective in showing the effect of iii) promoting the proliferation of skin cells, ii) promoting the synthesis of collagen, iii) inhibiting collagenase, iii) enhancing integrin expression, iii) antioxidant activity, or iii) a combination thereof. It is contained as an ingredient. At this time, the roe deer urine extract is preferably contained in 0.001% to 20.0% by weight relative to the total weight of the composition.
본 발명에 따르면, 노루오줌 추출물은 피부 자극이 없이 안정하며, 피부에 침투되어 피부 세포의 증식 촉진, 콜라겐의 합성 촉진, 콜라게네이즈의 억제, 인테그린 발현 증진, 및 항산화 작용 등의 효과를 가져 피부의 주름과 탄력을 개선하여 피부 노화를 효과적으로 방지하고 건강한 피부를 유지시킨다. According to the present invention, the roe deer urine extract is stable without skin irritation, and penetrates the skin to promote the proliferation of skin cells, promote the synthesis of collagen, inhibit collagenase, enhance the expression of integrin, and have antioxidant effects. Improves wrinkles and elasticity of the skin, effectively preventing skin aging and maintaining healthy skin.
이하 본 발명을 상세히 설명하다. Hereinafter, the present invention will be described in detail.
본 발명자들은 천연에서 자생하는 동식물들을 대상으로 피부 노화 효능 물질을 탐색하는 연구를 수행하였고, 그 결과 노루오줌 추출물이 피부 세포의 증식 촉진, 콜라겐 합성 촉진 및 분해 억제, 인테그린의 발현 증진 및 항산화 효능이 뛰어난 것을 확인하고 본 발명을 완성하였다. The present inventors conducted a study to search for skin aging agonist substances in native plants and animals, and as a result, the roe deer urine extract promotes the proliferation of skin cells, promotes collagen synthesis and inhibits degradation, enhances the expression of integrin, and antioxidant effects. It confirmed the outstanding thing and completed this invention.
노루오줌(Astilbe chinensis var. davidii)은 범의귀과에 속하는 여러해살이풀로서 전국의 산골짜기에서 흔히 볼 수 있고 높이는 30~70cm이고 긴 갈색털이 있으며, 근경은 굵고 옆으로 짧게 뻗는다. 잎은 3개씩 2~3회 갈라지며, 작은 잎은 타원형, 길이 3~8cm 나비 2~4cm, 종이처럼 얇고 가장자리에 겹톱니 또는 결각상의 톱니가 있고 잎자루가 길다. 꽃은 7~8월에 피고 홍자색, 줄기끝의 원추꽃차례에 길 이 30cm 정도로서 많은 꽃이 달리고, 화축에는 갈색 털이 많고, 꽃받침은 5개로 갈라지고 갈라진 조각은 달걀모양이며 꽃잎은 5개로서 선형이고 수술은 10개이며 암술대는 2개이고 삭과는 길이 3~4mm이다. 이러한 노루오줌의 전초(全草)를 소승마(小升麻) Astilbes Herba라하고 뿌리는 적승마(赤升麻) Astilbe Radix라고 해서 약용에 이용되는데 혈액순환을 좋게 하고, 어혈(瘀血)을 풀어주며, 열을 내리고, 독을 풀어주며, 경련을 멎게 하고, 통증을 멎게 하는 효능이 있어서 과로로 오는 병, 근육과 뼈마디가 시리고 아픈 증상, 타박상, 관절통, 수술 후 통증, 뱀에게 물린 독을 푸는 데 사용한다(한국의 약용식물, 교학사, 2000, p204, 배기환저). 민간에서는 적승마(赤升麻)라 불리는 이것의 근경을 해열, 진통, 소염 등에 사용하였고 소승마(赤小麻)라고 불리는 땅 위에서 자라는 부분은 해열, 진해 작용이 있으므로 감기로 인한 열, 기침, 두통과 몸살 기운이 있을 때 처방하고 사용되었다. 현재 보고된 바에 의하면 전초에는 시안화수소산, 꽃에는 케르세틴 그리고 근경에는 베르게닌과 탄닌 성분이 함유되어 있는 것으로 알려져 있다. 이 속(屬)에 속하는 식물로는 그 밖에 진퍼리노루오줌(A. divaricata), 숙은노루오줌(A. koreana), 외잎승마(A. simplicifolia) 등이 있다. Roe pee ( Astilbe) chinensis var. davidii ) is a perennial herb belonging to the genus Ophidae, commonly found in valleys all over the country, 30 ~ 70cm high, with long brown hairs, and rhizomes are thick and stretched shortly to the side. The leaves are divided into two or three times, three to three, and the small leaves are oval, 3 to 8 cm long, 2 to 4 cm wide, thin like paper, and have claws or crustal serrates on the edges and long petioles. Flowers bloom in July-August, reddish purple, with cones at the end of stems, about 30cm long, with many flowers running, flowers with brown hairs, calyxes split into 5, cracked pieces in the shape of eggs, 5 petals, linear It has 10 stamens, 2 pistils and 3 ~ 4mm long. These roe deer urine outposts are called horse riding horses Astilbes Herba and the roots of red horse riding horses Astilbe Radix are used for medicinal purposes. It is effective in releasing, lowering heat, releasing poison, relieving cramps, and relieving pain. It is used to solve (Korean medicinal plants, Kyohaksa, 2000, p204, exhaust ventilation base). In the private sector, it is used for fever, analgesia and anti-inflammatory, which is called red horse, and the part that grows on the ground called micro horse riding has antipyretic and antitussive action, so it is caused by cold, cough, It was prescribed and used for headaches and aches and pains. It has been reported that it contains hydrocyanic acid in the outpost, quercetin in the flowers, and vergenin and tannin in the rhizome. Plants belonging to the genus include A. divaricata, A. koreana and A. simplicifolia.
본 발명에 따른 화장료 조성물은 위와 같은 노루오줌 추출물을 함유하는 것이면 본 발명에 포함한다. 이때, 노루오줌 추출물은 피부 노화를 방지하는 유효성분으로 함유된다. 상기 노루오줌 추출물은 노루오줌의 뿌리를 추출용매를 사용하여 추출한 것이 바람직하다. 노루오줌 추출물은 당업계에서 공지된 다양한 추출 방법을 이용하여 수득할 수 있으며, 바람직하게는, (a) 물, (b) 탄소수 1-4의 무수 또는 함수 저급 알코올(메탄올, 에탄올, 프로판올, 부탄올 등), (c) 아세톤, (c) 에틸 아세테이트, (e) 클로로포름, 및 (f) 1,3-부틸렌글리콜로 이루어진 군중에서 선택된 하나 또는 둘 이상의 혼합 추출 용매를 이용하여 추출, 수득할 수 있다. The cosmetic composition according to the present invention is included in the present invention as long as it contains such a roe deer urine extract. At this time, the roe deer urine extract is contained as an active ingredient to prevent skin aging. The roe deer urine extract is preferably extracted from the root of the roe deer urine extract using a solvent. The roe deer extract can be obtained using various extraction methods known in the art, and preferably, (a) water, (b) anhydrous or hydrous lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, butanol) Etc.), (c) acetone, (c) ethyl acetate, (e) chloroform, and (f) one, two or more mixed extraction solvents selected from the group consisting of 1,3-butylene glycol. have.
본 발명에서 상기 노루오줌 추출물은 상기한 추출 용매뿐만 아니라, 다른 추출 용매를 이용하여 실질적으로 동일한 효과를 나타내는 것이면 본 발명에 포함한다. 또한, 본 발명에서 상기 노루오줌 추출물은 추출 용매에 의한 추출물뿐만 아니라, 통상적인 정제 과정을 거친 추출물도 포함한다. In the present invention, the roe deer urine extract is included in the present invention as long as it exhibits substantially the same effect using other extraction solvents as well as the aforementioned extraction solvents. In addition, the roe deer urine extract in the present invention includes not only an extract by the extraction solvent, but also an extract that has undergone a conventional purification process.
구체적으로, 본 발명에 사용되는 노루오줌 추출물은 추출 용매에 의한 추출물을 그대로 사용하거나, 추출한 후 정제 과정, 예를 들어 일정한 분자량 컷-오프 값을 갖는 한외 여과막 등의 분리막을 막 분리, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등의 정제 과정을 추가적으로 실시하여 사용할 수 있다. 아울러, 상기 노루오줌 추출물은 감압 증류 및 동결 건조(또는 분무 건조 등) 등과 같은 추가적인 과정에 의해 분말 상태로 제조된 다음, 조성물에 그대로 함유되거나, 또는 용매에 희석되어 함유될 수 있다. Specifically, the roe deer urine extract used in the present invention is used as it is, or extracted by the extraction solvent, after purification, for example, membrane separation membrane separation, such as an ultrafiltration membrane having a constant molecular weight cut-off value, various chromatography Purification procedures such as separation by (made for separation according to size, charge, hydrophobicity or affinity) can be used in addition. In addition, the roe deer urine extract may be prepared in a powder state by an additional process such as distillation under reduced pressure and freeze drying (or spray drying), and then contained in the composition as it is, or diluted in a solvent.
상기 노루오줌 추출물은, 바람직하게는 화장료 조성물 총 중량에 대해 0.001중량% ~ 20.0중량%로 함유된다. 이때, 노루오줌 추출물이 0.001중량% 미만으로 함유된 경우에는 세포 증식 촉진, 콜라겐 합성 촉진, 콜라겐 분해 억제, 인테그린 발현 증진, 항산화 효과 등의 피부 노화 방지 효과가 미미하며, 20.0 중량%를 초과하여 투입할 경우에는 초과 투입에 따른 상승효과가 적고 경제적으로 바람직하지 않 을 수 있다. 더욱 바람직하게는, 상기 노루오줌 추출물은 조성물 총 중량에 대해 0.01중량% ~ 10.0중량%로 함유된 것이 좋으며, 더더욱 바람직하게는 0.1중량% ~ 5.0중량%로 함유된 것이 좋다. 더욱 바람직하기로는 본 발명의 화장료 조성물이 상기 추출물들을 0.01 내지 10.0 중량%, 더더욱 바람직하게는 0.1-5.0 중량%를 포함하는 것이 좋다. The roe deer urine extract, preferably contained in 0.001% to 20.0% by weight relative to the total weight of the cosmetic composition. At this time, when the roe deer urine extract is contained less than 0.001% by weight, the skin anti-aging effects such as promoting cell proliferation, promoting collagen synthesis, inhibiting collagen degradation, enhancing integrin expression, and antioxidant effects are insignificant, and are added in excess of 20.0% by weight. In this case, the synergy effect of excess input may be small and economically undesirable. More preferably, the roe deer urine extract is preferably contained in 0.01% by weight to 10.0% by weight relative to the total weight of the composition, even more preferably contained in 0.1% by weight to 5.0% by weight. More preferably, the cosmetic composition of the present invention comprises 0.01 to 10.0% by weight of the extract, even more preferably 0.1 to 5.0% by weight.
본 발명에 따르면, 상기 노루오줌 추출물은 피부 세포의 증식 촉진 작용, 콜라겐의 합성 촉진 작용, 콜라게네이즈의 억제 작용, 인테그린의 발현 증진 작용, 뛰어난 항산화 작용 등을 나타내어 피부 주름을 개선시키고 피부의 탄력을 증진시켜 피부 노화를 방지한다. 이와 같은 사실은 하기의 실시예에 명시되어 있다. According to the present invention, the roe deer urine extract has an action of promoting the growth of skin cells, promoting the synthesis of collagen, inhibiting collagenase, enhancing the expression of integrin, excellent antioxidant action, etc. to improve skin wrinkles and elasticity of the skin Prevent skin aging. This fact is specified in the following examples.
본 발명에 따른 화장료 조성물은 노루오줌 추출물 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함하며, 예컨대 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함할 수 있다. The cosmetic composition according to the present invention includes components commonly used in cosmetic compositions in addition to the roe deer urine extract, and may include, for example, conventional auxiliaries such as stabilizers, solubilizers, vitamins, pigments and flavors, and carriers.
또한, 본 발명에 따른 화장료 조성물은 당업계에서 일반적인 제형, 예를 들어 유화 제형이나 가용화 제형 등의 형태로 제조될 수 있다. 유화 제형으로는 영양화장수, 크림, 에센스 등을 예로 들 수 있으며, 가용화 제형으로는 유연화장수를 예로 들 수 있다. 또한, 본 발명의 화장료 조성물은 화장품 이외에도 피부 과학적으로 허용 가능한 매질 또는 기제를 함유함으로써 피부과학 분야에서 통상적으로 사용되는 국소 적용 또는 전신 적용할 수 있는 보조제 형태로 제조될 수 있다. In addition, the cosmetic composition according to the present invention may be prepared in the form of a general formulation in the art, for example, an emulsion formulation or a solubilized formulation. Examples of the emulsified formulations include nutrient cosmetics, creams, essences, and the like. Examples of solubilized formulations include softening cosmetics. In addition, the cosmetic composition of the present invention can be prepared in the form of adjuvants that can be applied topically or systemically, which is commonly used in the field of dermatology by containing a dermatologically acceptable medium or base in addition to cosmetics.
적합한 화장품의 제형으로는 예를 들면, 용액, 겔, 고체 또는 반죽 무수 생성물, 수상에 유상을 분산시켜 얻은 에멀젼, 현탁액, 마이크로에멀젼, 마이크로캡 슐, 미세과립구 또는 이온형(리포좀), 비이온형의 소낭 분산제의 형태, 크림, 스킨, 로션, 파우더, 연고, 스프레이 또는 콘실 스틱(conceal stick)의 형태로 제공될 수 있다. 또한, 포말(foam)의 형태 또는 압축된 추진제를 더 함유한 에어로졸 조성물의 형태로도 제조될 수 있다. Suitable formulations of cosmetics include, for example, emulsions, suspensions, microemulsions, microcapsules, microgranules or ionics (liposomes), nonionics, obtained by dispersing an oil phase in a solution, gel, solid or pasty anhydrous product, aqueous phase. Can be provided in the form of a vesicle dispersant, cream, skin, lotion, powder, ointment, spray or conceal stick. It may also be prepared in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.
또한, 본 발명의 화장료 조성물은 노루오줌 추출물에 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제, 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온 봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 또는 피부과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 그리고 상기의 성분들은 피부과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다. In addition, the cosmetic composition of the present invention, in addition to the roe extract, fatty substances, organic solvents, solubilizers, thickening and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic Or nonionic emulsifiers, fillers, metal ion sequestrants and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or any other commonly used in cosmetics It may contain adjuvants conventionally used in the cosmetic or dermatological fields, such as ingredients. And the above ingredients may be introduced in amounts generally used in the field of dermatology.
본 발명의 화장료 조성물을 첨가할 수 있는 제품으로는, 예를 들어, 수렴화장수, 유연화장수, 영양화장수, 각종 크림, 에센스, 팩, 파운데이션 등과 같은 화장품류와 클렌징, 세안제, 비누, 트리트먼트, 미용액 등을 들 수 있다. Examples of products to which the cosmetic composition of the present invention may be added include, for example, cosmetics such as astringent cosmetics, soft cosmetics, nourishing cosmetics, various creams, essences, packs, foundations, and the like, cleansing agents, soaps, treatments, and essences. Etc. can be mentioned.
본 발명의 화장료 조성물의 구체적인 제형으로서는 스킨로션, 스킨 소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스처 로션, 영양로션, 맛사지크림, 영양크림, 모이스처 크림, 핸드크림, 에센스, 영양에센스, 팩, 비누, 샴푸, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션, 바디클렌저, 유액, 프레스파우더, 루스파우더, 아이섀도, 패취, 분무제 등의 제형을 포함한다. Specific formulations of the cosmetic composition of the present invention include skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, essence, nutrition essence, pack, Formulations such as soaps, shampoos, cleansing foams, cleansing lotions, cleansing creams, body lotions, body cleansers, emulsions, press powders, loose powders, eye shadows, patches, sprays and the like.
이상에서 설명한 본 발명에 따른 화장료 조성물은 노루오줌 추출물에 의해 피부의 주름과 탄력의 개선을 통해 피부 노화를 효과적으로 방지한다. 구체적으로 본 발명에 따르면, 상기 노루오줌 추출물은 피부 세포의 증식 촉진 작용, 콜라겐의 합성 촉진 작용, 콜라게네이즈의 억제 작용, 인테그린의 발현 증진 작용, 뛰어난 항산화 작용 등을 나타내어 피부 주름을 개선시키고 피부의 탄력을 증진시켜 피부 노화를 방지한다. 이와 같은 사실은 하기의 실시예에 명시되어 있다. The cosmetic composition according to the present invention described above effectively prevents skin aging through the improvement of wrinkles and elasticity of the skin by the roe deer urine extract. Specifically, according to the present invention, the roe deer urine extract improves skin wrinkles by showing the action of promoting the proliferation of skin cells, promoting the synthesis of collagen, inhibiting the action of collagenase, enhancing the expression of integrin, excellent antioxidant action, etc. Prevents skin aging by promoting elasticity. This fact is specified in the following examples.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명한다. 하기의 실시예는 본 발명을 보다 구체적으로 설명하기 위해 제공되는 것으로서, 본 발명의 기술적 범위가 이들 실시예에 의해 제한되지 않는다는 것은 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 있어서 자명할 것이다. Hereinafter, the present invention will be described in more detail with reference to Examples. The following examples are provided to explain the present invention in more detail, and it will be apparent to those skilled in the art that the technical scope of the present invention is not limited by these examples. will be.
[[ 제조예Production Example ]]
< 노루오줌 추출물의 제조 ><Preparation of roe deer urine extract>
노루오줌의 근경을 깨끗이 씻어 잘 말린 후 작은 조각으로 파쇄하고 에틸알코올 및 물이 7:3으로 섞여 있는 수용액에 침전시켜 5일간 추출한 후 300메쉬 여과포로 여과하고, 다시 와트만 5번 여과지로 여과한 후, 회전 감압증발기로 건조하여, 건조 중량 47g/㎏을 얻었다. 건조된 노루오줌 추출 파우더를 50% 1,3-부틸렌 글리콜에 용해하여 다음과 같이 사용하였다.Roots of roe deer urine were washed thoroughly and dried well, then broken into small pieces, precipitated in an aqueous solution containing ethyl alcohol and water at 7: 3, extracted for 5 days, filtered through a 300 mesh filter cloth, and filtered through a filter paper of Wattman 5 again. Then, it dried with the rotary vacuum evaporator and obtained dry weight 47g / kg. The dried roe deer urine extract powder was dissolved in 50% 1,3-butylene glycol and used as follows.
[[ 실험예Experimental Example 1] One]
< 피부 세포 증식 효과 실험 >Skin cell proliferation effect experiment
노루오줌 추출물이 피부 세포 증식에 미치는 효과를 알아보기 위하여 인체 정상 섬유아세포(한국세포주은행)를 96-웰 마이크로 플레이트(96-well microplate)의 각 웰에 1 x 104 세포가 되도록 접종하고, DMEM 배지(Sigma사)에서 24시간 동안 37℃에서 배양하였다. 이어서, 상기 제조예의 노루오줌 추출물이 최종 농도 0.01%, 0.05%, 0.1%, 0.5% 및 1%로 포함된 혈청이 없는 DMEM 배지로 교체한 실험군과 노루오줌 추출물이 포함되지 않은 혈청이 없는 DMEM 배지로 교체한 대조군을 24시간 동안 추가로 배양하였다. 그런 다음, MTT 용액(3-(4,5-디메틸티아졸-2-일) 2,5-디페닐테트라졸륨 브로마이드: 5 mg/㎖)을 각각 10 ㎕씩 첨가하고, 4시간 동안 배양한 후, 배지를 제거하고, 각 웰 당 100 ㎕의 DMSO 용액을 가하여 20분 동안 진탕 시키고, 마이크로 플레이트 판독기 (microplate reader, Molecular Devices, 미합중국)를 이용하여 570 nm에서 상층액의 흡광도를 측정하였다. 측정값을 하기의 수학식 1에 대입하여 세포 증식 효과를 산출하고, 그 결과를 하기 [표 1]에 나타내었다.In order to examine the effect of roe deer urine extract on skin cell proliferation, human normal fibroblasts (Korea Cell Line Bank) were inoculated to 1 x 10 4 cells in each well of a 96-well microplate, and DMEM Incubated at 37 ° C. for 24 hours in medium (Sigma). Subsequently, the experimental group in which the roe deer urine extract of the preparation was replaced with the serum-free DMEM medium containing the final concentrations of 0.01%, 0.05%, 0.1%, 0.5%, and 1% and the DMEM medium without serum containing the roe deer extract Controls replaced with were further incubated for 24 hours. Then, 10 μl each of MTT solution (3- (4,5-dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide: 5 mg / ml) was added thereto, followed by incubation for 4 hours. The medium was removed, shaken for 20 minutes by adding 100 μl of DMSO solution per well, and the absorbance of the supernatant was measured at 570 nm using a microplate reader (Molecular Devices, USA). The measured values were substituted into the following Equation 1 to calculate the cell proliferation effect, and the results are shown in the following [Table 1].
상기 [표 1]에서 나타낸 바와 같이, 노루오줌 추출물을 처리하지 않은 대조군과 비교하여, 노루오줌 추출물이 처리된 실험군의 경우 매우 높은 섬유아세포 증식 효과를 나타냄을 알 수 있었다. As shown in [Table 1], compared to the control group not treated with roe deer urine extract, it can be seen that the experimental group treated with roe deer urine extract showed a very high fibroblast proliferation effect.
[[ 실험예Experimental Example 2] 2]
< 콜라겐 합성 증진 효과 실험 ><Collagen Synthesis Enhancement Experiment>
인체 정상 섬유아세포(한국세포주은행)를 96-웰 마이크로 플레이트의 각 웰에 2 x 104 세포가 되도록 접종하고, DMEM 배지에서 37℃에서 24시간 동안 배양하였다. 이어서, 상기 제조예의 노루오줌 추출물이 최종 농도 0.01, 0.05 및 0.10%로 포함된 혈청이 없는 DMEM 배지로 교체한 실험군과 추출물이 포함되지 않은 혈청이 없는 DMEM 배지로 교체한 대조군을 48시간 동안 추가로 배양하였다. 배양 후, 각 웰의 상층액을 모아 프로콜라겐 (procollagen) 타입 I C-펩타이드 (PICP) 양을 키트 (Takara, 일본국)를 이용하여 측정함으로써 새로 합성된 콜라겐 양을 측정하였다. 측정된 양은 ng/2x104 세포로 환산하였으며, 그 결과를 하기 [표 2]에 나타나 있다.Human normal fibroblasts (Korea Cell Line Bank) were seeded to 2 x 10 4 cells in each well of a 96-well microplate and incubated for 24 hours at 37 ° C in DMEM medium. Subsequently, the experimental group in which the roe deer urine extract of the above preparation was replaced with serum-free DMEM medium containing the final concentrations of 0.01, 0.05, and 0.10% and the control group replaced with the serum-free DMEM medium without the extract were further added for 48 hours. Incubated. After incubation, the supernatant of each well was collected and the amount of newly synthesized collagen was measured by measuring the amount of procollagen (procollagen) type I C-peptide (PICP) using a kit (Takara, Japan). The measured amount was converted into ng / 2 × 10 4 cells, and the results are shown in the following [Table 2].
상기 [표 2]에 나타난 바와 같이, 노루오줌 추출물을 처리하지 않은 대조군과 비교하여, 노루오줌 추출물이 처리된 실험군의 경우 매우 높은 콜라겐 합성량을 보임을 알 수 있었다. 그리고 노루오줌 추출물의 농도가 증가함에 따라 향상된 합성량을 보여 노루오줌 추출물은 탁월한 콜라겐 합성 증진 효과를 나타냄을 확인할 수 있었다. As shown in [Table 2], compared to the control group not treated with the roe deer urine extract, it can be seen that the experimental group treated with roe deer urine extract showed a very high collagen synthesis amount. And as the concentration of roe deer urine extract increased, it showed that the roe deer urine extract showed an excellent collagen synthesis enhancing effect.
[[ 실험예Experimental Example 3] 3]
< < 콜라게네이즈Collagenase 억제 효과 실험 > Inhibitory Effect Experiment>
노루오줌 추출물의 콜라게네이즈 생성 억제능을 알아보고자 다음과 같이 측정하였다. To determine the collagenase production inhibitory ability of roe deer urine extract was measured as follows.
실험은 2.5 %의 우태아 혈청이 함유된 DMEM (Dulbecco's Modified Eagle's Media) 배지가 함유된 96웰 평판배양기 (96-well microtiter plate)에 인간의 섬유아세포를 2x104 세포/웰(well)이 되도록 넣고, 70~80% 정도 자랄 때까지 배양하였다. 그리고 제조예의 노루오줌 추출물을 농도별로 24시간 동안 처리한 후, 세포배양액을 채위하였다. 채위한 세포배양액을 상업적으로 이용 가능한 콜라게네이즈 측정기구 (미국 아머샴파마샤 사. Catalog #: RPN 2610)를 이용하여 콜라게네이즈 생성 정도를 측정하였다. 먼저 1차 콜라게네이즈 항체가 균일하게 도포된 96-웰 평판 (96-well plate)에 채위된 세포 배양액을 넣고 3시간 동안 항원-항체 반응을 항온조에서 실시하였다. 3시간 후 발색단이 결합된 2차 콜라겐 항체를 96-웰 평판 (96-well plate)에 넣고 다시 15분간 반응시켰다. 15분 후 발색유발물질을 넣어 실온에서 15분간 발색을 유발시키고, 다시 1M 황산을 넣어 반응(발색)을 중지시켰다. 반응액의 색깔은 노란색을 띄었으며 반응 진행의 정도에 따라 노란색의 정도가 다르게 나타났다. 노란색을 띈 96-웰 평판 (96-well plate)의 흡광도를 흡광계를 이용하여 405nm에서 측정하고 콜라게네이즈의 합성 정도를 계산하였다. 이때 조성물을 처리하지 않은 군의 채위된 세포배양액의 반응 흡광도를 대조군으로 하였다. 이와 같이, 세포에서의 콜라게네이즈 발현의 저해를 측정한 결과 in vitro 에서 실험군은 하기 [표 3]에 보인 바와 같이 콜라게네이즈 발현을 저해함을 확인하였다. 발현 저해능은 비처리군(대조군)의 합성능을 100으로 하여 대비한 것이다. Experiments were performed by placing human fibroblasts into 2x10 4 cells / well in a 96-well microtiter plate containing Dulbecco's Modified Eagle's Media (DMEM) medium containing 2.5% fetal calf serum. Incubate until 70-80% growth. And after treating the roe deer urinary extract of the preparation for 24 hours for each concentration, the cell culture was collected. The cultured cell culture solution was measured by using a commercially available collagenase measuring instrument (Amersham Pharmacia Co., Catalog #: RPN 2610). First, the cultured cells were placed in a 96-well plate uniformly coated with primary collagenase antibody, and the antigen-antibody reaction was performed in a thermostat for 3 hours. After 3 hours, the chromophore-conjugated secondary collagen antibody was placed in a 96-well plate and reacted again for 15 minutes. After 15 minutes, the coloring stimulant was added to cause color development at room temperature for 15 minutes, and 1M sulfuric acid was added again to stop the reaction (color development). The color of the reaction solution was yellow and the degree of yellow color was different according to the progress of the reaction. The absorbance of the yellowish 96-well plate was measured at 405 nm using an absorbance meter and the degree of synthesis of collagenase was calculated. At this time, the reaction absorbance of the prepared cell culture medium of the group not treated with the composition was used as a control. As such, as a result of measuring the inhibition of collagenase expression in cells, it was confirmed that the experimental group inhibited collagenase expression as shown in Table 3 below in vitro. Expression inhibition capacity is prepared by setting the synthetic ability of the untreated group (control) to 100.
상기 [표 3]에 나타난 바와 같이, 세포에서의 콜라게네이즈 발현 저해를 측정한 결과 노루오줌 추출물은 콜라네이즈의 발현을 억제함을 확인할 수 있었다.As shown in [Table 3], as a result of measuring collagenase expression inhibition in cells, it was confirmed that the roe deer urine extract inhibited the expression of collagenase.
[[ 실험예Experimental Example 4] 4]
< < 인테그린Integreen β1 발현 증진 효과 실험 > β1 Expression Enhancement Effect Experiment>
인체 정상 섬유아세포를 48-웰 마이크로 플레이트의 각 웰에 1 x 106 세포가 되도록 접종하고, DMEM 배지에서 37℃에서 24시간 동안 배양하였다. 이어서, 상기 제조예의 노루오줌 추출물이 최종 농도 0.01%, 0.05%, 0.1%, 0.5% 및 1%로 포함된 혈청이 없는 DMEM 배지로 교체한 실험군과 노루오줌 추출물이 포함되지 않은 혈청이 없는 DMEM 배지로 교체한 대조군을 24시간 동안 추가로 배양하였다. 배양 후, EIA(Enzyme immnoassay)법에 따라 인테그린 β1의 발현 정도를 측정하였다(MK008 키트, Takara, 일본). 구체적으로, 원심분리로 세포를 회수하고 세포추출액을 제조한 후 항-인테그린 β1 항체가 코팅되어있는 웰에 상기 세포추출액을 처리하였다. 이차 항체를 첨가하고 4℃에서 45분간 반응시킨 후 OPD(ο-Phenylenediamine-HCl)로 검출하였다. 염색되어있는 OPD를 OPD 용해액으로 용해한 후 530nm에서 엘라이자 리더로 흡광도를 측정하여 평가하였다. 그 결과를 하기 [표 4]에 나타내었다. Human normal fibroblasts were seeded to 1 × 10 6 cells in each well of a 48-well microplate and incubated for 24 hours at 37 ° C. in DMEM medium. Subsequently, the experimental group in which the roe deer urine extract of the preparation was replaced with the serum-free DMEM medium containing the final concentrations of 0.01%, 0.05%, 0.1%, 0.5%, and 1% and the DMEM medium without serum containing the roe deer extract Controls replaced with were further incubated for 24 hours. After incubation, the expression level of integrin β1 was measured by EIA (Enzyme immnoassay) method (MK008 kit, Takara, Japan). Specifically, the cells were recovered by centrifugation, the cell extracts were prepared, and the cell extracts were treated in wells coated with anti-integrin β1 antibody. Secondary antibody was added and reacted at 4 ° C. for 45 minutes and then detected by OPD (ο-Phenylenediamine-HCl). The stained OPD was dissolved in the OPD solution, and then absorbance was measured by using an ELISA reader at 530 nm. The results are shown in the following [Table 4].
상기 [표 4]에 나타난 바와 같이, 노루오줌 추출물은 농도 의존적으로 세포의 접착에 중요한 작용을 수행하는 인테그린 β1의 합성을 촉진하는 것을 확인할 수 있었다. As shown in [Table 4], it was confirmed that the roe deer urine extract promotes the synthesis of integrin β1 which plays an important role in cell adhesion in a concentration-dependent manner.
[[ 실험예Experimental Example 5] 5]
< 항산화 효과 실험 ><Antioxidant Effect Test>
노루오줌 추출물의 항산화 효과를 알아보기 위하여, 다음과 같이 자유라디칼 소거활성 실험(Free Radical Scavenging Activity Test)을 실시하였다. To investigate the antioxidant effect of roe deer urine extract, Free Radical Scavenging Activity Test was conducted as follows.
자유라디칼 소거활성 실험은 Kim 등(Kor. J. Pharmacogn., 24(4), 299-303(1993))의 방법을 변형한 것으로써, 안정한 자유라디칼인 DPPH(1,1-diphenyl-2-picryhydrazyl, 시그마사) 시약을 사용하였다.DPPH 용액(Blank인 경우는 에탄올) 150 ㎕에 상기 추출물을 다양한 농도로 제작하여, 이들을 각각 150 ㎕ 첨가하여 혼합하고, 실온에서 30분간 방치한 후 517 nm에서 흡광도를 측정하는 실험군을 설정하였으며, 이에 대한 대조군으로는 정제수를 이용한 경우로 설정하였다. 상기 실험군과 대조군에 대한 흡광도 측정 후, 하기 수학식 2를 이용하여 자유라디칼 소거활성 효과를 구하여 그 결과를 하기 [표 5]에 나타내었다.The free radical scavenging activity was modified from the method of Kim et al. (Kor. J. Pharmacogn., 24 (4), 299-303 (1993)), and the stable free radical DPPH (1,1-diphenyl-2- picryhydrazyl (Sigma Co., Ltd.) reagent was used. 150 μl of DPPH solution (ethanol in the case of Blanc) was prepared at various concentrations, and 150 μl of these extracts were mixed, mixed, and allowed to stand at room temperature for 30 minutes, followed by 517 nm. An experimental group for measuring absorbance was set, and the control group was set to the case using purified water. After absorbance measurement for the experimental group and the control group, the free radical scavenging activity was obtained using Equation 2 below and the results are shown in the following [Table 5].
상기 [표 5]에 나타낸 바와 같이, 노루오줌 추출물은 자유라디칼 소거능력이 매우 탁월하다는 것을 확인할 수 있었다.As shown in [Table 5], the roe deer urine extract was confirmed that the free radical scavenging ability is very excellent.
[[ 실시예Example ]]
노루오줌 추출물을 함유하는 화장료의 피부 주름 및 탄력 개선 효과에 대한 임상 시험을 실시하기 위해 하기 [표 6]과 같은 성분과 함량으로 화장료 조성물을 제조하였다. 구체적인 제조방법은 다음과 같다. In order to conduct a clinical test on the skin wrinkle and elasticity improving effect of the cosmetic containing the roe deer urine extract, a cosmetic composition was prepared with the ingredients and contents as shown in the following [Table 6]. Specific manufacturing method is as follows.
1) 하기 [표 6]에 나타낸 성분 1-6을 혼합, 교반하면서 70℃로 가온하여 유상 용액을 만들었다. 1) The components 1-6 shown in the following [Table 6] were heated to 70 ° C. while mixing and stirring to prepare an oily solution.
2) 정제수에 7-8, 10-11을 넣어 교반하면서 70℃로 가온하여 수상 용액을 만들었다. 2) 7-8 and 10-11 were added to purified water and warmed to 70 ° C. while stirring to prepare an aqueous solution.
3) 상기 2)의 수상 용액에 유상 용액인 1)과 원료 9를 혼합한 후, 유화시켜 냉각하였다. 3) After mixing 1) and the raw material 9 which are oily solutions to the aqueous solution of said 2), it emulsified and cooled.
4) 상기 3)에 원료 13, 14를 첨가하여 혼합하고 30℃까지 냉각시켜 제조하였다. 4) The raw materials 13 and 14 were added to 3), mixed, and cooled to 30 ° C.
[[ 비교예Comparative example ]]
노루오줌 추출물을 함유시키지 않은 것을 제외하고는 상기 실시예와 동일하게 조성하였다. 본 비교예의 구체적인 성분과 함량은 하기 [표 6]과 같다. Except for containing the roe deer urine extract was prepared in the same manner as in the above example. Specific components and contents of this Comparative Example are as shown in the following [Table 6].
[[ 실험예Experimental Example 6] 6]
< 피부 주름 개선 효과 실험 ><Skin wrinkle improvement effect experiment>
본 발명에 따라서 노루오줌 추출물을 함유하는 화장료 조성물의 피부 주름 개선 효과를 알아보고자 건강한 35세에서 50세의 여성 20명을 대상으로 측정하였다. To determine the skin wrinkle improvement effect of the cosmetic composition containing a roe deer urine extract according to the present invention was measured in 20 healthy women aged 35 to 50 years.
먼저 A와 B 두 그룹으로 나누고, A 그룹에는 실시예를, B 그룹에는 비교예의 제형을 안면부에 하루 2회씩(아침 및 저녁) 3개월간 도포하게 하였다. 3개월 후 주름의 개선 정도를 피험자의 설문 및 주름의 영상 분석을 통해 평가하였다. First, A and B were divided into two groups, and the group A was given an example, and the group B was applied to the formulation of the comparative example twice a day (morning and evening) for 3 months. After 3 months, the degree of wrinkle improvement was evaluated by subject's questionnaire and image analysis of wrinkles.
피험자의 설문은 사용전과 비교하여 개선 없음, 약간의 개선, 중등도의 개선, 상당한 개선의 4단계로 판단하였으며, 그 결과를 하기 [표 7]에 나타내었다.The subject's questionnaire was judged as four stages of no improvement, slight improvement, moderate improvement, and significant improvement compared to before use, and the results are shown in the following [Table 7].
또한, 주름의 영상분석을 위해, 실험이 시작되기 전 눈 밑의 레플리카를 채취하고 실험이 종료된 직후의 레플리카를 눈 밑의 동일 부위에서 채취하여 영상분석을 통해 주름의 2차원적 분석으로 주름의 밀도를 측정하였다. 영상분석에 의한 주름 밀도의 측정 결과는 사용 전에 대한 주름 밀도에 대한 감소율로 계산하여 하기 [표 8]에 나타내었다. In addition, for image analysis of wrinkles, a replica under the eye is taken before the experiment is started, and a replica immediately after the experiment is completed at the same site under the eye. The density was measured. The measurement results of wrinkle density by image analysis are shown in Table 8 below, calculated as a reduction ratio against wrinkle density before use.
상기 [표 7] 및 [표 8]에 나타난 바와 같이, 노루오줌 추출물을 함유한 실시예의 경우, 비교예에 비해 피부 주름 개선 효과가 매우 우수함을 알 수 있었다.As shown in [Table 7] and [Table 8], in the case of the Example containing roe deer urine extract, it was found that the skin wrinkle improvement effect is very excellent compared to the comparative example.
[[ 실험예Experimental Example 7] 7]
< 피부 탄력 효과 실험 ><Skin Elasticity Test>
본 발명에 따라서 노루오줌 추출물을 함유하는 화장료 조성물의 피부 탄력 증진 효과를 알아보고자 다음과 같이 측정하였다. According to the present invention to determine the skin elasticity enhancing effect of the cosmetic composition containing the roe deer urine extract was measured as follows.
온도 24~26℃, 습도 75%의 조건에서 20세 이상의 건강한 여성 20명(평균연령 37세)을 A와 B 두 그룹으로 나누고, A 그룹에는 실시예를, B 그룹에는 비교예의 제형을 눈가를 중심으로 하루 2회씩(아침 및 저녁) 12주간 도포하게 한 후, 피부탄력 측정기(Cutometer MPA580, Conrage + Khazaka사, 독일연방국)를 이용하여 피부 탄력 정도를 측정하였다. 그 결과는 하기 [표 9]와 같다. 결과는 cutometer MPA580의 R8(R8(12주)-R8(0주)) 값으로 나타냈으며, R8 값은 피부 점탄성(Vicoelasticity)의 성질로서 값이 클수록 피부 탄력 효과가 우수함을 의미한다.20 healthy women (average age 37 years) of 20 years or older (average age 37 years) were divided into two groups A and B, and the formulation of Comparative Example was compared to group B. After applying twice a day (morning and evening) for 12 weeks, the skin elasticity was measured using a skin elasticity measuring instrument (Cutometer MPA580, Conrage + Khazaka, Germany). The results are shown in the following [Table 9]. The results were expressed as R8 (R8 (12 weeks) -R8 (0 weeks)) of cutometer MPA580, and R8 value is a property of skin viscoelasticity.
상기 [표 9]에 나타난 바와 같이, 노루오줌 추출물을 함유한 실시예가 비교예에 비해 피부 탄력 효과가 매우 우수함을 확인할 수 있었다.As shown in Table 9, the Example containing the roe deer urine extract was confirmed that the skin elasticity effect is very excellent compared to the comparative example.
[[ 실험예Experimental Example 8] 8]
< 제형 안정성 실험 >Formulation Stability Experiment
본 발명에 따라서 노루오줌 추출물을 함유한 화장료에 대한 제형 안정성을 알아보고자 하기와 같은 방법으로 실시하였다. According to the present invention was carried out in the following method to determine the formulation stability for the cosmetic containing the roe deer urine extract.
먼저, 화장료의 안정성을 시험하기 위해 상기 실시예 및 비교예에 따른 화장료 조성물을 45℃로 일정하게 유지되는 항온조에서 불투명 초자 용기에 담아 12주 동안 보관하고, 또한 4℃로 일정하게 유지되는 완전히 차광된 냉장고 내에서 불투명 초자 용기에 담아 12주 동안 보관한 후, 변색 및 변취, 분리정도를 비교 측정하였다. 그 결과는 하기 [표 10]과 같다. 이때 제품 변색 및 변취, 분리정도를 다음의 6등급으로 분류하여 평가하였다. First, in order to test the stability of the cosmetics, the cosmetic composition according to the above Examples and Comparative Examples was kept in an opaque glass container in a thermostat maintained at 45 ℃ constant for 12 weeks, and also completely shaded at 4 ℃ After storing for 12 weeks in an opaque glass container in the refrigerator, discoloration, deodorization, and separation were measured. The results are shown in Table 10 below. At this time, the product discoloration, odor, and separation were evaluated by classifying into the following six grades.
< 등급 ><Grade>
0 : 변화 없음 0: no change
1 : 극히 조금 분리(변색)1: very little separation (discoloration)
2 : 조금 분리(변색)2: A little separation (discoloration)
3 : 조금 심하게 분리(변색)3: Slightly separated (discolored)
4 :심하게 분리(변색)4: severely separated (discolored)
5 : 극히 심하게 분리(변색)5: extremely severe separation (discoloration)
상기 [표 10]에 나타낸 바와 같이, 실시예 및 비교예에 화장료 조성물은 45℃에서 변색이나 변취, 분리 현상이 거의 없이 안정하였고, 이는 노루오줌 추출물이 제형 내에서 안정한 상태로 존재함을 나타낸다.As shown in Table 10, the cosmetic compositions in Examples and Comparative Examples were stable at 45 ° C. with little discoloration, discoloration, or separation, indicating that the roe deer urine extract was present in a stable state in the formulation.
이하에서는, 이상의 실험예의 결과를 근거로 하여 본 발명에 따라서 노루오줌 추출물을 함유하는 화장료 조성물의 제형예를 제시한다. 그러나 본 발명의 조성물을 하기의 제형예들로 한정하고자 하는 것은 아니다. Hereinafter, on the basis of the results of the above experimental example will be presented a formulation example of the cosmetic composition containing a roe deer urinary extract according to the present invention. However, the composition of the present invention is not intended to be limited to the following formulation examples.
[[ 제형예Formulation example 1] One]
< 유연화장수(스킨로션) ><Softener (Skin Lotion)>
하기 [표 11]에 보인 성분과 함량으로 통상의 방법에 따라 유연화장수를 제조하였다. According to the conventional method with the components and contents shown in the following [Table 11] was prepared a flexible cosmetic water.
[[ 제형예Formulation example 2] 2]
< 영양화장수(<Nutritional Cosmetics ( 밀크로션Milk Croissant ) >)>
하기 [표 12]에 보인 성분과 함량으로 통상의 방법에 따라 영양화장수를 제조하였다. To nutrient cosmetics was prepared according to the conventional method with the ingredients and contents shown in the following [Table 12].
[[ 제형예Formulation example 3] 3]
< 영양크림 ><Nutrition Cream>
하기 [표 13]에 보인 성분과 함량으로 통상의 방법에 따라 영양크림을 제조하였다. Nutritional creams were prepared according to a conventional method with the ingredients and contents shown in the following [Table 13].
[[ 제형예Formulation example 4] 4]
< 마사지크림 ><Massage cream>
하기 [표 14]에 보인 성분과 함량으로 통상의 방법에 따라 마사지크림을 제조하였다. Massage creams were prepared according to a conventional method with the ingredients and contents shown in the following [Table 14].
[[ 제형예Formulation example 5] 5]
< 팩 ><Pack>
하기 [표 15]에 보인 성분과 함량으로 통상의 방법에 따라 팩을 제조하였다. A pack was prepared according to a conventional method with the ingredients and contents shown in the following [Table 15].
상술한 바와 같이, 본 발명에 따른 화장료 조성물은 노루오줌 추출물을 함유 하여 피부 노화를 방지하는 효과를 갖는다. 구체적으로, 노루오줌 추출물이 피부 세포의 증식을 촉진시키고 섬유아세포의 콜라겐 합성 촉진 및 분해를 억제하며 인테그린의 발현을 증진시키고 뛰어난 항산화 효과를 가져 피부 주름을 개선시키고 피부의 탄력을 증진시켜 피부 노화를 방지한다. 또한 본 발명의 화장료 조성물은 피부에 자극이 없는 안전한 물질로서, 화장수, 에센스, 로션, 크림, 팩, 젤, 연고, 패취, 또는 분무제 등의 제형으로 유용하게 이용될 수 있다.As described above, the cosmetic composition according to the present invention contains the roe deer urine extract has an effect of preventing skin aging. Specifically, roe deer urine extract promotes the proliferation of skin cells, inhibits the synthesis and synthesis of fibroblasts collagen, promotes the expression of integrins, has an excellent antioxidant effect, improves skin wrinkles and improves the elasticity of the skin, thereby improving skin aging. prevent. In addition, the cosmetic composition of the present invention is a safe substance having no skin irritation, and may be usefully used in the formulation of lotion, essence, lotion, cream, pack, gel, ointment, patch, or spray.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020070037245A KR20080093500A (en) | 2007-04-17 | 2007-04-17 | Roe deer urine extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020070037245A KR20080093500A (en) | 2007-04-17 | 2007-04-17 | Roe deer urine extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20080093500A true KR20080093500A (en) | 2008-10-22 |
Family
ID=40153990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020070037245A Ceased KR20080093500A (en) | 2007-04-17 | 2007-04-17 | Roe deer urine extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20080093500A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101135193B1 (en) * | 2009-12-02 | 2012-04-23 | (주)더페이스샵 | Cosmetic Composition containing Lysophosphatidylcholine and Astilbe chinensis var Extracts stabilized with nanoliposome for improving skin wrinkle |
| KR101993847B1 (en) * | 2018-11-28 | 2019-06-27 | (주)그린솔루션스 | Cosmetic composition for improving skin wrinkles or skin moisturizing with native plants in DMZ |
| KR102044891B1 (en) * | 2019-05-17 | 2019-11-14 | (주)그린솔루션스 | Cosmetic composition for improving skin wrinkles or skin moisturizing with native plants in DMZ |
| KR20200002672A (en) * | 2018-06-29 | 2020-01-08 | 의료법인사과나무의료재단 | Composition for prevention or treatment of dental disease comprising an extract of Astilbe chinesis |
| KR20200075598A (en) * | 2018-12-18 | 2020-06-26 | 재단법인 경기도경제과학진흥원 | Composition for Improving Pulmonary Fibrosis Using an Extract of Astilbe rubra |
-
2007
- 2007-04-17 KR KR1020070037245A patent/KR20080093500A/en not_active Ceased
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101135193B1 (en) * | 2009-12-02 | 2012-04-23 | (주)더페이스샵 | Cosmetic Composition containing Lysophosphatidylcholine and Astilbe chinensis var Extracts stabilized with nanoliposome for improving skin wrinkle |
| KR20200002672A (en) * | 2018-06-29 | 2020-01-08 | 의료법인사과나무의료재단 | Composition for prevention or treatment of dental disease comprising an extract of Astilbe chinesis |
| KR101993847B1 (en) * | 2018-11-28 | 2019-06-27 | (주)그린솔루션스 | Cosmetic composition for improving skin wrinkles or skin moisturizing with native plants in DMZ |
| KR20200075598A (en) * | 2018-12-18 | 2020-06-26 | 재단법인 경기도경제과학진흥원 | Composition for Improving Pulmonary Fibrosis Using an Extract of Astilbe rubra |
| KR102044891B1 (en) * | 2019-05-17 | 2019-11-14 | (주)그린솔루션스 | Cosmetic composition for improving skin wrinkles or skin moisturizing with native plants in DMZ |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20200026646A (en) | Cosmetic Composition for Improving Skin Condition Comprising Plant cell complex cultures to improve skin radiance and vitality | |
| KR101928797B1 (en) | Composition of skin external application containing compound K | |
| KR101504908B1 (en) | Compositions for enhancing skin barrier comprising extract of Boehmeria nivea | |
| KR20110110052A (en) | Skin cosmetic composition comprising soybean extract containing cumestrol or cumestrol | |
| KR101312965B1 (en) | The cosmetic composition for anti-wrinkle comprising the mixture of extract of Allium cepa, Symphytum officinale, Eclipta prostrate, and Theobroma cacao | |
| KR20040043192A (en) | Substances capable of potentiating laminin 5 productivity in epidermal cells and utilization thereof | |
| KR20030064059A (en) | Cosmetic composition containing paeonia suffruticosa andrews extract and albizzia julibrissin dura extract having anti-ageing effect | |
| KR102168532B1 (en) | Cosmetic composition for enhancing skin elasticity or improving skin wrinkle containing herb extracts | |
| KR20080093500A (en) | Roe deer urine extract | |
| KR100903654B1 (en) | Cosmetic composition containing Hachocho extract and adenosine | |
| KR101917645B1 (en) | Cosmetic composition comprising saccharomyces ferment filtrate, asparagus officinalis stem extract and tussilago farfara flower extract | |
| KR20110030802A (en) | Cosmetic composition for improving wrinkles containing palmitoyl oligopeptide and worm extract | |
| KR20140018666A (en) | Composition for skin external application containing fermented soybean extract | |
| KR101214344B1 (en) | Cosmetics composition containing fermented rice bran and licorice extract | |
| KR20180100093A (en) | Composition of skin external application containing ginsenoside F1 | |
| KR101909533B1 (en) | Composition of skin external application containing ginsenoside F1 | |
| KR101909578B1 (en) | External composition for skin containing extract of Potentilla stolonifera var. quelpaertensis Nakai | |
| KR20100093223A (en) | Cosmetic composition containing an extract of ophiopogon japonicus for skin miosture | |
| KR20090055079A (en) | Cosmetic composition for preventing skin aging containing wild yam extract | |
| KR101808222B1 (en) | Composition for improving skin elasticity containing sphallerocarpus gracilis extract | |
| KR20160003918A (en) | Cosmetic composition for enhancing skin elasticity or improving skin wrinkle containing herb extracts | |
| KR100772336B1 (en) | Cosmetic composition containing niosome stabilized yulpi and gaza extract | |
| KR20090078084A (en) | Cosmetic composition for improving skin wrinkles containing tofu extract and adenosine | |
| KR100374161B1 (en) | Skin care composition containing Phytosphingosine and Morus alba Extract | |
| KR20020090544A (en) | Whitening and wrinkle improvement cosmetics composition containing areca catechu extract and arbutin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20070417 |
|
| PA0201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20080221 Patent event code: PE09021S01D |
|
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20080808 Patent event code: PE09021S02D |
|
| PG1501 | Laying open of application | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20090120 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20080808 Comment text: Final Notice of Reason for Refusal Patent event code: PE06011S02I Patent event date: 20080221 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |